EU reviewers have recommended marketing approval for two new medicines, but have turned down another product. 

The European Medicines Agency is meeting this week to decide whether two new drugs, including one that enhances anti-parkinsonian activity, should be approved for use in the EU. Also, the sponsor of a treatment for the rare degenerative muscle disorder, Pompe disease, is expected to attend an oral explanation meeting to address last-minute questions.

Stada’s Thornton & Ross UK subsidiary has launched a generic version of Seretide, known as Advair in the US, marking its first push into the respiratory arena.

The deal leaves PRX004 in the capable hands of Novo Nordisk, which is hoping to expand beyond obesity and diabetes, while Prothena can focus on the rest of its pipeline.